Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 159568, 6 pages
http://dx.doi.org/10.5402/2012/159568
Clinical Study

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

1Barbara Ann Karmanos Cancer Institutte, Wayne State University School of Medicine, Detroit, MI 48201, USA
2Division of Hematology/Oncology, St. John Hospital, Wayne State University School of Medicine, 19229 Mack Avenue, Grosse Pointe Woods, Detroit, MI 48236, USA

Received 1 January 2012; Accepted 22 January 2012

Academic Editors: M. Emoto and M. Santarosa

Copyright © 2012 Zyad Kafri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. L. Clayman, S. M. Lippman, G. E. Laramore, and W. K. Hong, “Head and neck cancer,” Cancer Medicine, pp. 1645–1710, 1997. View at Google Scholar
  2. A. I. Dreyfuss, J. R. Clark, C. M. Norris et al., “Docetaxel: an active drug for squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1672–1678, 1996. View at Google Scholar · View at Scopus
  3. G. Catimel, J. Verweij, V. Mattijssen et al., “Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck,” Annals of Oncology, vol. 5, no. 6, pp. 533–537, 1994. View at Google Scholar · View at Scopus
  4. C. Couteau, N. Chouaki, S. Leyvraz et al., “A phase II study of docetaxel in patients wtth metastatic squamous cell carcinoma of the head and neck,” British Journal of Cancer, vol. 81, no. 3, pp. 457–462, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Inuyama, A. Kataura, K. Togawa et al., “Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer,” Gan To Kagaku Ryoho, vol. 26, no. 1, pp. 107–116, 1999. View at Google Scholar · View at Scopus
  6. B. S. Glisson, B. A. Murphy, G. Frenette, F. R. Khuri, and A. A. Forastiere, “Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1593–1599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Schoffski, G. Catimel, A. S. T. Planting et al., “Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck: results of a phase II study of the EORTC Early Clinical Studies Group,” Annals of Oncology, vol. 10, no. 1, pp. 119–122, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Specht, S. K. Larsen, and H. S. Hansen, “Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck,” Annals of Oncology, vol. 11, no. 7, pp. 845–849, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. D. Colevas, S. Adak, P. C. Amrein, J. J. Barton, R. Costello, and M. R. Posner, “A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck,” Annals of Oncology, vol. 11, no. 5, pp. 535–539, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Genet, D. Cupissol, N. Tubiana-Mathieu et al., “Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study,” American Journal of Clinical Oncology, vol. 27, no. 5, pp. 472–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Galetta, V. Gebbia, F. Giotta et al., “Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale,” Lung Cancer, vol. 38, no. 1, pp. 79–84, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Pelegri, L. Calvo, J. Florian et al., “Every other week combination of gemcitabine and docetaxel as first line therapy in advanced breast cancer patients: preliminary results from a phase II trial,” Breast Cancer Research and Treatment, vol. 69, pp. 270–356, 2001. View at Google Scholar · View at Scopus
  13. K. Syrigos, E. Karapanagiotou, A. Charpidou et al., “Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study,” Journal of Chemotherapy, vol. 19, no. 4, pp. 438–443, 2007. View at Google Scholar · View at Scopus
  14. R. C. Shepard, D. Levy, J. D. Berlin et al., “Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298): a trial of the Eastern Cooperative Oncology Group,” Oncology, vol. 66, no. 4, pp. 303–309, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. E. S. Casper, M. R. Green, D. P. Kelsen et al., “Phase II trial of gemcitabine (2,2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas,” Investigational New Drugs, vol. 12, no. 1, pp. 29–34, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Carmichael, K. Possinger, P. Phillip et al., “Advanced breast cancer: a phase II trial with gemcitabine,” Journal of Clinical Oncology, vol. 13, no. 11, pp. 2731–2736, 1995. View at Google Scholar · View at Scopus
  17. J. B. Sorensen, “Gemcitabine in non-small cell lung cancer,” Lung Cancer, vol. 12, no. 1, pp. S173–S175, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Lund, O. P. Hansen, K. Theilade, M. Hansen, and J. P. Neijt, “Phase II study of gemcitabine (2,2-difluorodeoxycytidine) in previously treated ovarian cancer patients,” Journal of the National Cancer Institute, vol. 86, no. 20, pp. 1530–1533, 1994. View at Google Scholar · View at Scopus
  19. G. Catimel, J. B. Vermorken, M. Clavel et al., “A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck,” Annals of Oncology, vol. 5, no. 6, pp. 543–547, 1994. View at Google Scholar · View at Scopus
  20. C. N. Rittenberg, R. J. Gralla, and J. T. Cole, “Preventing docetaxel induced fluid retention: the efficacy of corticosteroids,” in Proceedings of the American Society of Clinical Oncology (ASCO '96), vol. 15, p. 531, 1996.
  21. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar · View at Scopus
  22. R. Simon, “Optimal two-stage designs for phase II clinical trials,” Controlled Clinical Trials, vol. 10, no. 1, pp. 1–10, 1989. View at Google Scholar · View at Scopus
  23. E. Lee and J. W. Wang, Statistical Methods for Survival Data Analysis, John Wiley & Sons, New York, NY, USA, 3rd edition, 2003.
  24. M. R. Posner, D. M. Hershock, C. R. Blajman et al., “Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer,” The New England Journal of Medicine, vol. 357, no. 17, pp. 1705–1715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus